scholarly journals Comparison of Levetiracetam and sodium Valproate in the prevention of migraine: a randomized clinical trial study

Author(s):  
Vahid Abbasi ◽  
Abolfazl Atalu ◽  
Perham Seddighnia

Background: Sodium valproate is an anti-seizure drug used for prophylactic use of migraine headaches. Despite the efficacy of this drug due to complications that cause some patients to not tolerate the drug. The purpose of this study was to Comparison of levotiracetam and Sodium valproate in migraine prophylaxis.Methods: This is a clinical trials study. 100 migraineurs who referred to the Alavi neurology clinic and indicated the onset of prophylaxis of migraine were studied in two groups of 50, one of which was a group of levetiracetam and another group of sodium valproate Received. Patients received daily 500mg of drug for 3 months and the effect of the drug on the number of attacks, severity of attacks, and MIDAS score was measured. Collected data analyzed by statistical methods in SPSS version 19. P<0.05 was considered as significant.Results: In both cases, significant improvement was observed in the number of attacks, severity and MIDAS score. In all of the criteria, levetiracetam and sodium valproate were almost identical, except for reducing the number of headache attacks that had a significantly in levothyramine group less than sodium valporoste group (P = 0.0001).Conclusions: This study showed that levothyramineacetamin can be used as a good alternative in those who do not tolerate sodium valproate.

2016 ◽  
Vol 18 (9) ◽  
Author(s):  
Farhad Assarzadegan ◽  
Hanif Tabesh ◽  
Seyed-Mostafa Hosseini-Zijoud ◽  
Andrew David Beale ◽  
Arya Shoghli ◽  
...  

2005 ◽  
Vol 2 (1) ◽  
pp. 72-79 ◽  
Author(s):  
Jennifer Litchfield ◽  
Jenny Freeman ◽  
Henrik Schou ◽  
Mark Elsley ◽  
Robert Fuller ◽  
...  

2021 ◽  
Vol 4 (4) ◽  
pp. 613-616
Author(s):  
Dun-Xian Tan ◽  
Russel J Reiter

SARS-CoV-2 has ravaged the population of the world for two years. Scientists have not yet identified an effective therapy to reduce the mortality of severe COVID-19 patients. In a single-center, open-label, randomized clinical trial, it was observed that melatonin treatment lowered the mortality rate by 93% in severely-infected COVID-19 patients compared with the control group (see below). This is seemingly the first report to show such a huge mortality reduction in severe COVID-19 infected individuals with a simple treatment. If this observation is confirmed by more rigorous clinical trials, melatonin could become an important weapon to combat this pandemic.


Background and Aim: Headache is the most common cause of referral to a physician. Two approaches of the migraine treatment include: treat the acute attacks and prevent future attacks. In this regard, the aim of this study was to investigate the effect of three drugs lutiracetam, sodium valproate and nortriptyline in the control of migraine headaches in patients with migraine in Birjand Neurology Clinic. Materials and Methods: This study is a quasi-experimental study. According to the physician, 120 migraine patients were divided into one of three groups: Lutiracetam with a daily dose of 250 mg, sodium valproate 500 mg and nortriptyline 25 mg for 4 weeks. Patientschr('39') information was collected through a questionnaire. Then the data were analyzed by SPSS) Version 16) software by using chi-square, paired t-test, and ANOVA. Results: 120 patients were divided into three groups of 40 patients. The mean age of the subjects was 33±11 years, 53.3% of them were female and 46.7% of them were male. In total, 46.7% of patients had severe headache before taking these three drugs. None of them had severe headache after taking the drug and 77.5% of them had mild headache. Lutiracetam group showed the greatest decrease in headache intensity. (P=0.01). Conclusion: Levetiracetam appears to be more effective than the other two drugs, especially sodium valproate, in reducing different degrees of headache.


2002 ◽  
Vol 57 (2) ◽  
pp. 83-88 ◽  
Author(s):  
Edson Duarte Moreira ◽  
Ezra Susser

In observational studies, identification of associations within particular subgroups is the usual method of investigation. As an exploratory method, it is the bread and butter of epidemiological research. Nearly everything that has been learned in epidemiology has been derived from the analysis of subgroups. In a randomized clinical trial, the entire purpose is the comparison of the test subjects and the controls, and when there is particular interest in the results of treatment in a certain section of trial participants, a subgroup analysis is performed. These subgroups are examined to see if they are liable to a greater benefit or risk from treatment. Thus, analyzing patient subsets is a natural part of the process of improving therapeutic knowledge through clinical trials. Nevertheless, the reliability of subgroup analysis can often be poor because of problems of multiplicity and limitations in the numbers of patients studied. The naive interpretation of the results of such examinations is a cause of great confusion in the therapeutic literature. We emphasize the need for readers to be aware that inferences based on comparisons between subgroups in randomized clinical trials should be approached more cautiously than those based on the main comparison. That is, subgroup analysis results derived from a sound clinical trial are not necessarily valid; one must not jump to conclusions and accept the validity of subgroup analysis results without an appropriate judgment.


Author(s):  
Daniel S. Tsze ◽  
Tamar R. Lubell ◽  
Robert C. Carter ◽  
Lauren S. Chernick ◽  
Kerrin C. DePeter ◽  
...  

PEDIATRICS ◽  
1985 ◽  
Vol 76 (4) ◽  
pp. 622-623
Author(s):  
NIGEL PANETH ◽  
SYLVAN WALLENSTEIN

The therapeutic trial comparing extracorporeal membrane oxygenation with conventional treatment in neonatal respiratory failure reported by Bartlett et al (Pediatrics 1985;76:479-487) uses a method of comparing treatments unlikely to be familiar to most pediatricians. Known as the "randomized play the winner" method, it has thus far been little used in clinical research. Most clinical investigators consider the conventional randomized clinical trial to be the last word in treatment comparisons. But randomized clinical trials are costly, cumbersome, and to some observers less than ideal ethically. The ethical problem arises from the fact that during a "successful" randomized clinical trial (ie, one that demonstrates a significant advantage to one treatment) about half of the trial subjects will receive a treatment which, at the end of the trial, will be known to be inferior.


2011 ◽  
pp. 1738-1758
Author(s):  
Tillal Eldabi ◽  
Robert D. Macredie ◽  
Ray J. Paul

This chapter reports on the use of simulation in supporting decision-making about what data to collect in a randomized clinical trial (RCT). We show how simulation also allows the identification of critical variables in the RCT by measuring their effects on the simulation model’s “behavior.” Healthcare systems pose many of the challenges, including difficulty in understanding the system being studied, uncertainty over which data to collect, and problems of communication between problem owners. In this chapter we show how simulation also allows the identification of critical variables in the RCT by measuring their effects on the simulation model’s “behavior.” The experience of developing the simulation model leads us to suggest simple but extremely valuable lessons. The first relates to the inclusion of stakeholders in the modeling process and the accessibility of the resulting models. The ownership and confidence felt by stakeholders in our case is, we feel, extremely important and may provide an example to others developing models.


Sign in / Sign up

Export Citation Format

Share Document